Sullivan Christopher Ryan — SEC Form 4 filings

SEC reporting owner CIK 1810417. 15 Form 4 filings on record with FilingPulse; latest filed 2026-09-18.

Transaction summary — filings shown

Covers all 15 filings on record, filed 2024-08-14 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Avalo Therapeutics, Inc. (AVTX)Chief Financial Officer1517 legs · 193,784 sh · $3,723,03527

Form 4 filings — Sullivan Christopher Ryan

FiledFormIssuerReported transactionsSource
2026-09-184Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 12,394 @ $9.88 · Sale (S): 12,394 @ $16.33 · Option exercise (M): 12,394 (derivative) @ $0EDGAR
2026-09-114Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 10,185 @ $8.04 · Sale (S): 10,185 @ $17.62 · Option exercise (M): 10,185 (derivative) @ $0EDGAR
2026-08-194Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 37,945 @ $9.88 · Option exercise (M): 2,876 @ $9.88 · Sale (S): 37,945 @ $19.85 · Sale (S): 3,749 @ $19.94 · Option exercise (M): 31,031 @ $9.88 · Sale (S): 31,031 @ $20.05 · +3 moreEDGAR
2026-06-124Avalo Therapeutics, Inc. (AVTX)Tax withholding (F): 138 @ $13.10EDGAR
2026-05-264Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 39,900 @ $0EDGAR
2026-05-114Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 18,606 @ $9.88 · Sale (S): 18,606 @ $24.12 · Option exercise (M): 18,606 (derivative) @ $0EDGAR
2026-05-074Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 47,000 @ $8.04 · Sale (S): 13,834 @ $18.55 · Sale (S): 12,347 @ $19.28 · Sale (S): 2,700 @ $20.76 · Sale (S): 9,219 @ $21.37 · Sale (S): 8,900 @ $22.57 · +1 moreEDGAR
2026-05-014Avalo Therapeutics, Inc. (AVTX)Sale (S): 8,458 @ $13.09 · Sale (S): 8,457 @ $13.23EDGAR
2026-04-034Avalo Therapeutics, Inc. (AVTX)Sale (S): 500 @ $15.86 · Sale (S): 7,479 @ $16.83 · Sale (S): 6,200 @ $17.02 · Sale (S): 1,780 @ $17.57EDGAR
2026-03-314Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 24,200 · Tax withholding (F): 8,241 @ $13.89 · Option exercise (M): 24,200 (derivative) @ $0EDGAR
2026-03-024Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 105,000 (derivative) @ $0EDGAR
2025-12-124Avalo Therapeutics, Inc. (AVTX)Tax withholding (F): 155 @ $4.10EDGAR
2025-04-014Avalo Therapeutics, Inc. (AVTX)Option exercise (M): 24,200 · Tax withholding (F): 7,285 @ $8.46 · Option exercise (M): 24,200 (derivative) @ $0EDGAR
2025-01-304Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 163,000 (derivative) @ $0EDGAR
2024-08-144Avalo Therapeutics, Inc. (AVTX)Grant/award (A): 186,700 (derivative) @ $0 · Grant/award (A): 72,600 (derivative) @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1810417 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →